Printer Friendly

POLYCELL, INC. SIGNS CROSS-LICENSE AGREEMENT WITH HYBRITECH INCORPORATED

POLYCELL, INC. SIGNS CROSS-LICENSE AGREEMENT WITH HYBRITECH INCORPORATED
 DETROIT, June 4 /PRNewswire/ -- PolyCell, Inc., a subsidiary of Quest BioTechnology, Inc. (NASDAQ: QBIO), announced today that it signed a cross-license agreement with Hybritech Incorporated. Under the terms of the agreement, PolyCell and Hybritech will each receive a license to the other company's bispecific antibody patents.
 "This agreement ends the Interference declared by the U.S. Patent Office between Hybritech and PolyCell and allows PolyCell's U.S. patents to remain in force," said Jayson D. Pankin, chairman and president of PolyCell and vice president of Quest.
 PolyCell is a development stage company organized to develop and commercialize the proprietary QUADROMA(TM) technology which produces bispecific antibodies primarily for cancer, cardiovascular and autoimmune disease therapeutic and diagnostic applications.
 Quest is a development stage company organized to acquire and commercialize health care products and technologies. Quest has two wholly owned subsidiaries, PolyCell, Inc. and Quest Blood Substitute, Inc., which were organized to license and commercialize Quest's health care products and technologies.
 -0- 6/4/92
 /CONTACT: Yvonne L. Marschner-Bova, director, Investor Relations, PolyCell, Inc., 313-871-4151/
 (QBIO) CO: PolyCell, Inc.; Hybritech Incorporated ST: Michigan IN: MTC HEA SU: LIC


JG -- DE012 -- 6978 06/04/92 10:43 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 4, 1992
Words:203
Previous Article:VAN DORN DECLARES QUARTERLY DIVIDEND
Next Article:THE RELIABLE CORPORATION WILL ADD OFFICE PRODUCTS SUPERSTORE; BATTLE CREEK OUTLET WILL OPEN JUNE 25, 1992
Topics:


Related Articles
Drug company buys antibody firm.
STERLING WINTHROP AND BIOMIRA SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
BIOMIRA AND STERLING WINTHROP SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
ENZON GRANTS BRISTOL-MYERS SQUIBB LICENSE FOR SCA(R) PROTEIN TECHNOLOGY
TELIOS APPOINTS FORMER ELI LILLY & COMPANY EXECUTIVE DONALD W. GRIMM AS CHIEF EXECUTIVE OFFICER
DURA PHARMACEUTICALS APPOINTS DAVID S. KABAKOFF AS EXECUTIVE VICE PRESIDENT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters